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Introduction: Paracrine effects can be exploited in cell-based therapies that secrete factors, such as chemokines
and cytokines, and can recruit inflammatory cells to transplants. In this study, mouse adipose tissue-derived stromal
cells (ASCs) and bone marrow-derived stromal cells (ST2 cells) were used to examine changes in paracrine interactions
with inflammation cells.
Methods: Green fluorescent protein positive (GFP+) bone marrow cells (BMCs) were injected into an irradiated mouse
via the femoral vein, and ASCs and ST2 cells were transplanted intradermally. Subsequently, an in vivo imaging system
was used to observe behaviors of GFP+ BMCs. To detect bone marrow-derived inflammatory cells which migrated to
the ASC and ST2 cell transplantation area, the sections were immunostained using antibodies against Gr1, CD11c, and
F4/80, and secretory proteins were detected in culture medium using enzyme-linked immunosorbent assay.
Results: Many bone marrow-derived inflammatory cells migrated to ASC and ST2 cell transplantation sites. Among
these, neutrophils were detected during the early period and macrophages were predominantly detected at a later
point in time. Many chemokines, cytokines, growth factors, matrix metalloproteinases (MMPs), and tissue inhibitors of
metalloproteinases (TIMPs) were secreted in abundance from ASCs, and the secretion increased by co-culturing with
inflammatory cells, except for secretions of insulin-like growth factor-1, MMP-9 and MMP-13. Although secretions from
ST2 cells were less than those from ASCs, co-culture with inflammatory cells increased these secretions to levels similar
to those of ASCs. However, unlike ASCs, the ST2 cells did not secrete angiostatin, MMP-2, or MMP-3. Finally, ASCs
secreted not only proinflammatory cytokines, angiogenic factors and MMPs but also anti-inflammatory cytokines,
anti-angiogenesis factors, and TIMPs.
Conclusions: The effects of cell-based therapies using ASCs and ST2 cells are depended on paracrine effects that
are mediated by chemokines, cytokines, growth factors, MMPs, and TIMPs, which comprise responses to interactions
between transplanted cells and inflammatory cells. Moreover, paracrine effects of transplanted cells are influenced by
inflammatory cells, and are moderated by a balance of secreted inhibitors.Introduction
Numerous previous studies report the effects of cell-
derived paracrine factors, and adipose tissue- and bone
marrow-derived cells have been used as sources for clin-
ical treatments and trials [1]. However, prognostic as-
sessments vary [2] and expectations of treatment effects
are often not met [3,4]. Thus, in addition to advanta-
geous effects, the disadvantageous side effects of these
cell types should be investigated prior to therapeutic use.* Correspondence: h2@ndmc.ac.jp
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article, unless otherwise stated.Wound healing is a complex and dynamic process that
is influenced by many factors, including cytokines,
growth factors, and chemokines [5], and is characterized
by precisely programmed phases of coagulation, inflam-
mation, proliferation, and remodeling [6]. Although
inflammation is an indispensable biological process, ex-
cessive inflammation causes tissue damage and disrupts
engraftment of transplanted cells. Previously, we showed
that inflammation was involved in cell transplantation [7].
After subcutaneous transplantation of adipose tissue-Central. This is an Open Access article distributed under the terms of the
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flammatory cells, including granulocytes, neutrophils,
monocytes, and macrophages, migrated toward ASC
transplants; their interactions with ASCs led to secretion
of various inflammatory and angiogenic factors and in-
duced extensive angiogenesis [7].
Currently, paracrine effects have been found to play
important roles in tissue regeneration and repair [8]
and are under consideration as mechanisms that can be
exploited in cell-based therapies. In particular, mesen-
chymal stem/stromal cells from bone marrow and adi-
pose tissues secrete a wide variety of cytokines and
growth factors that may be involved in tissue repair
[8-10]. Although the paracrine effect is important for
tissue regeneration, it remains unclear whether it can
be exploited in the treatment of all diseases. Moreover,
although transplantation of ASCs induces inflamma-
tion, it is unclear whether this may be effective against
autoimmune and chronic inflammatory diseases, such
as rheumatoid arthritis, osteoarthritis, and diabetic ul-
cers, and subsequent excess inflammation may have
deleterious effects.
In the present study, we initially determined the spe-
cificity of paracrine mechanisms for ASC transplants.
Subsequently, we compared the effects of ASCs and
bone marrow-derived stromal cells (ST2 cells) during
the inflammatory stage of wound healing, and investi-
gated their competence as sources for cell-based
therapies.Methods
Preparation of cells
The Ethics Committee of Animal Care and Experimen-
tation of the National Defense Medical College (Saitama,
Japan) approved the protocol for animal treatment and
the intended procedures of the present study. ASCs were
prepared from inguinal adipose tissues of 8-week-old
male C57BL/6 mice (Japan SLC, Shizuoka, Japan).
Adipose tissues were extensively washed in Dulbecco’s
modified Eagle’s medium (DMEM) and were digested
for 2 hours at 37°C with 0.1% collagenase type I. The
samples were resuspended in DMEM, passed through a
40-μm nylon mesh, and then centrifuged at 1,600 rpm
for 10 minutes. Cell pellets were resuspended in lysis
buffer for a few minutes, DMEM was added, and cells
were resuspended and centrifuged at 1,600 rpm for
10 minutes. The cells were then resuspended in DMEM
containing 5% heat-inactivated fetal bovine serum and
antibiotics (control medium) and were plated. ASCs
were subcultured every 4 days and were used in experi-
ments after two passages. Bone marrow-derived stromal
cells (ST2 cells) were purchased from Riken BioResource
Center (Ibaraki, Japan).Flow cytometric analyses
At least 2 × 105 cells were suspended in 30 μL
phosphate-buffered saline (PBS) containing 1% fetal bo-
vine serum and incubated for 20 minutes in the presence
of phycoerythrin-labeled antibodies specific for CD29,
Sca-1, CD90.2, CD105, CD73, CD117, CD34, CD133,
CD45, Gr-1, CD11c, and F4/80, or with fluorescein
isothiocyanate-labeled antibodies against CD31 (Beckman
Coulter, Fullerton, CA, USA). Nonspecific fluorescence
was determined using immunoglobulin G for each anti-
body isotype (eBioscience, San Diego, CA, USA).
Migration of green fluorescent protein positive bone
marrow cells to tissue surrounding a wound, and into the
ASC and ST2 cell transplantation area
In vivo imaging was performed using fluorescent labeled
cells and an OV110 system (Olympus, Tokyo, Japan) as
previously described [7]. Green fluorescent protein-
positive (GFP+) bone marrow cells (BMCs) were extracted
by flushing femurs and tibias of male C57BL/6-Tg (CAG-
eGFP) mice aged 8 to 13 weeks (Japan SLC). C57BL/6
mice were then irradiated with 6 Gy and hairs were re-
moved from an ear using depilatory cream. On the follow-
ing day, GFP+ BMCs (2.0 × 107 cells/mouse) were injected
into tail veins. One day later, a 2.0-mm hole was made in
the center of both ears of each mouse using a metal ear
punch (Natsume Seisakusho Co. Ltd, Tokyo, Japan) to
produce a regenerative dermal tissue model. ASCs and
ST2 cells were labeled with PKH26 (Sigma–Aldrich, St.
Louis, MO, USA) and suspended in PBS. Subsequently,
PKH26-labeled ASCs and ST2 cells (2.0 × 106 cells/
5 μL) were transplanted into mouse ears 1 day after in-
jections of GFP+ BMCs as described above, and 5 μL
normal saline solution of Japanese Pharmacopoeia was
injected as a negative control. Transplanted PKH26-
labeled cells and migrating GFP+ BMCs were then ob-
served using an OV110 system. During observation,
anesthesia was induced by inhalation of 1.5% isoflurane
in oxygen.
Immunostaining
Mice were anesthetized with pentobarbital (Kyoritsu
Seiyaku Co., Tokyo, Japan) and were perfusion-fixed
with 4% paraformaldehyde. Ears were then removed and
cryoembedded in optimum cutting temperature com-
pound (Sakura Finetek, Tokyo, Japan), and 10-μm sec-
tions were cut using a cryostat. Cryosections were
refixed in 4% paraformaldehyde for 15 minutes and were
incubated for 1 hour at room temperature in PBS con-
taining skin milk. After blocking, cryosections were in-
cubated for 1 hour with primary biotinylated antibodies
specific for Gr-1, CD11c, and F4/80 (1:50 dilutions;
eBioscience). Cryosections were then incubated for
30 minutes with allophycocyanin-conjugated streptavidin
Table 1 Comparison of cell markers in ASCs and ST2 cells
using flow cytometry
Marker ASCs ST2 cells
CD29 95 ± 2 92 ± 2
Sca1 90 ± 1 74 ± 2
CD90.2 90 ± 1 5.3 ± 0.5
CD105 21 ± 1 3.7 ± 0.4
CD73 13 ± 2 7.5 ± 0.6
CD117 5.1 ± 0.8 11.5 ± 2
CD34 1 ± 1 0







Percentage expressions of marker proteins are presented as means ± standard
deviation. ASC, adipose tissue-derived stromal cell; ST2 cell, bone marrow-derived
stromal cell.
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using Hoechst 33258 (Dojindo Laboratories, Kumamoto,
Japan).
Isolation of inflammatory cells
Male C57BL/6 mice (Japan SLC; 8 to 13 weeks old) re-
ceived intraperitoneal transplantations of 2 mL 12% so-
dium casein in saline. Gr-1+ cells in peritoneal cavities
were then collected by laparotomy 1 day after induction,
and CD11c+ cells and F4/80+ cells were collected after
7 days. Cell populations were separated to high purity
(>97%) using a magnetic cell sorting method (Miltenyi
Biotec, Bergisch Gladbach, Germany) with antibodies
against Gr-1, CD11c, and F4/80.
Detection of secreted factors
ASCs and ST2 cells were plated at 5.0 × 104 cells/well in 48-
well culture plates (Sumitomo Bakelite Co., Tokyo, Japan)
and were allowed to attach overnight. Subsequently, superna-
tants were replaced and equal numbers of Gr-1+, CD11c+,
and F4/80+ cells were added. After 2 days of culture, the con-
centrations of secreted proteins were measured from the
supernatant using Bio-Plex assays (Bio-Rad, Hercules, CA,
USA) for the macrophage inflammatory proteins (MIP)-1α,
MIP-1β, and MIP-2, keratinocyte-derived chemokine (KC),
granulocyte-colony stimulating factor (G-CSF), monokine in-
duced by interferon γ (MIG), interleukin (IL)-6, and vascular
endothelial growth factor (VEGF). Enzyme-linked immuno-
sorbent assays were used to detect monocyte chemotactic
protein (MCP)-1 (Thermo Fisher, Boston, MA, USA), hep-
atocyte growth factor (HGF), insulin-like growth factor
(IGF)-1, matrix metalloproteinase (MMP)-3 (R&D Systems,
Minneapolis, MN, USA), MMP-2, MMP-9 (Uscn Life Sci-
ence Inc., Hubei, PRC), MMP-13, angiostatin (Biosensis Pty
Ltd, South Australia, Australia), and tissue inhibitors of metal-
loproteinase (TIMP)-1 and -2 (Raybiotec Inc., Norcross, GA,
USA).
Statistical analyses
Data are expressed as the mean ± standard deviation.
Multiple comparisons were performed using analysis of
variance with Dunnett’s test as appropriate. Differences
were considered significant at P < 0.05.
Results
Cell markers of ASCs and ST2 cells
Cell markers of ASCs (passage two) and ST2 cells were
identified using flow cytometry. ASCs expressed high
levels of CD29, Sca-1, and CD90.2, whereas ST2 cells
expressed high levels of CD29. Although both cell types
expressed high levels of CD29, the markers CD34,
CD117, Gr-1, CD11b, CD31, CD106, CD133, CD45,
CD11c, and F4/80 were not detected in either cell type
(Table 1).Migration of GFP+ bone marrow cells to tissue surrounding
a wound, and to ASC and ST2 cell transplantation area
Five hours after perforation of mouse ears with GFP+
BMC transplants, GFP+ cells migrated towards the hole
(Figure 1A). Many GFP+ BMCs gradually migrated into
the tissue around the hole (an additional movie file
shows this in more detail, see Additional file 1), although
the rate of migration decreased after peaking at 1 to
2 weeks, and the wound gradually closed (Figure 1B).
The present mouse model was designed to identify
BMCs that are related to wound healing. Accordingly,
migration of GFP+ BMCs to the transplantation area
was detected about 6 hours after transplantation with
ASCs and ST2 cells, and accumulated in this area with
time (Figure 1C-E; an additional movie file shows this
in more detail, see Additional file 2). The migration of
GFP+ BMCs toward transplantation area did not differ
between ASCs and ST2 cells, and comparatively few
BMCs migrated following injections of saline solution
into ears (Figure 1F).
Induction of inflammation following cell transplantation
One day after the holes were made in the ears, the mi-
grated cells were predominantly Gr-1+. However, the
presence of these cells peaked on day 3 and decreased to
almost undetectable levels by day 7 (Figure 2A). In con-
trast, F4/80+ cells were not present on day 1 but were
observed in the tissue surrounding the hole after day 3
(Figure 2B). On the day after ASC and ST2 cell trans-
plantation, many migratory GFP+ cells were found to be
positive for the granulocyte and neutrophil marker Gr-1
Figure 1 Observation of green fluorescent protein-positive (GFP+) bone marrow cells (BMCs) migrating to tissue surrounding a wound, and to
adipose tissue-derived stromal cell (ASC) and bone marrow-derived stromal cell (ST2) transplantation area. (A) Bright field images of an ear in
which was punched a hole (left two panels) and fluorescence images with a fluorescent filter for GFP (right two panels) at 5 hours after perforation.
GFP+ BMCs migrated to tissue surrounding the hole (right panel). (B) Temporal changes in migration of GFP+ BMCs and sizes of holes. (C) Fluorescence
images were taken using a fluorescent filter for GFP at 6 hours and at 3 days after intradermal transplantation of ASCs into mouse ears. GFP+ BMCs
gradually migrated towards ASC transplantation area; arrows show the migrated GFP+ BMCs. (D,E) Fluorescence images of GFP+ BMC migration at 1
and 7 days after transplantation of PKH26 (red)-labeled ASCs (D) and PKH26-labeled ST2 cells (E); images were taken using fluorescent filters for red
fluorescent protein and GFP. (F) Fluorescence images at 1 and 7 days after saline injection. All scale bars = 2 mm.
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cells were present. However, very few of these cells were
present after 7 days. In contrast, F4/80+ cells (macro-
phages) were not observed on day 1 after cell transplant-
ation but were present in the transplantation area after
7 days (Figure 2D) and included both GFP-positive and
-negative cells. CD11c+ cells were detected on days 3
and 7 (Figure 2E) and their numbers marginally varied
during the experiment. F4/80+ cell migration was more
pronounced following transplantation of ASCs and ST2
cells than in tissue surrounding perforations. Although,
both ASCs and ST2 cells were engrafted in the tissue at
3 days after transplantation, some transplanted cells had
been disrupted after 7 days (Figure 2F).
Inflammatory factors induced by interactions of ASCs or
ST2 cells with inflammatory cells
Inflammatory cells migrated toward the transplantation
sites of both ASCs and ST2 cells (Figure 2). Hence cyto-
kine and chemokine levels were determined in superna-
tants from cultured cells (Figure 3). In these experiments,
ASCs secreted MIP-1α, MIP-1β, MIP-2, KC, MCP-1, and
IL-6. However, differences between ASCs and ST2 cells
were much greater than those anticipated from in vivo
data (Figure 1C-E). Thus, ASCs or ST2 cells were co-cultured with Gr-1+, F4/80+, or CD11c+ cells. In these ex-
periments, large quantities of secreted chemokines and
cytokine were found in the media of monoculture of
ASCs, and ASCs co-cultured with Gr-1+, CD11c+, or F4/
80+ cells increased the secretions (Figure 3). Although
monocultured ST2 cells had little secretory activity, the
presence of Gr-1+, CD11c+, or F4/80+ cells promoted che-
mokine secretion from ST2 cells as well as ASCs. In par-
ticular, MIP-2 was absent in supernatants from
monocultures of ST2 cells but was detected at levels simi-
lar to that in monocultures of ASCs after co-culture with
inflammatory cells. Thus, paracrine secretions from both
ASCs and ST2 cells were markedly increased in the pres-
ence of Gr-1+, F4/80+, or CD11c+ cells.
Secretion of angiogenesis factors following interactions
of ASCs or ST2 cells with inflammatory cells
Angiogenic growth factors such as VEGF, HGF, and
IGF-1 were measured in monoculture supernatants and
in media from co-cultures of ASCs or ST2 cells with
Gr-1+, F4/80+, or CD11c+ cells (Figure 4). ASCs abun-
dantly secreted angiogenic growth factors alone and in
co-culture with inflammatory cells. However, in com-
parison with monocultured ST2 cells, co-culture ST2
cells with Gr-1+, F4/80+ or CD11c+ cells increased the
Figure 2 Identification of migrated cells, and morphological changes of transplanted adipose tissue-derived stromal cells (ASCs) and bone
marrow-derived stromal cells (ST2). (A) Immunostaining of Gr-1 (red) at 1, 3, and 7 days after perforation and green fluorescent protein-positive
(GFP+) bone marrow cell (BMC) migration (green). Scale bars = 50 μm. (B) Immunostaining of F4/80 (red) at 1, 3, and 7 days after perforation and
GFP+ BMC migration (green). Scale bars = 50 μm. (C) Immunostaining of Gr-1 (red) at 1 day after transplantation of ASCs or ST2 cells and GFP+
BMC migration (green). Scale bars = 100 μm. (D) Immunostaining of F4/80 (red) at 7 days after transplantation of ASCs or ST2 cells and migration
of GFP+ BMCs (green). Scale bars = 100 μm. (E) Immunostaining of CD11c (red) at 3 days after transplantation of ASCs or ST2 cells and GFP+ BMC
migration (green). Scale bars = 100 μm. (F) Morphological changes of PKH26-labeled ASCs and ST2 cells (red) on days 3 and 7 after transplantation.
Transplanted cells were engrafted after 3 days but were disrupted after 7 days. Arrows show lipids from PKH26 (lipophilic dye) linked membranes of
burst cells. Scale bars = 50 μm. Nuclear staining was performed using Hoechst 33258 (blue).
Figure 3 Secretions of the chemokines MIP-1α, MIP-1β, MIP-2, KC, and MCP-1 and the cytokine IL-6 following co-culture of ASCs or ST2 cells with
Gr1+, F4/80+, or CD11c+ cells. Comparisons are made with monocultures (non). Data are presented as means ± standard deviation. *P < 0.0001,
**P < 0.0005, ***P < 0.01, ****P < 0.05, versus monocultured cells; Dunnett’s test (n = 5). ASC, adipose tissue-derived stromal cell; IL, interleukin; KC,
keratinocyte-derived chemokine; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; N.D., not detected; ST2 cell, bone
marrow-derived stromal cell.
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Figure 4 Secretions of the angiogenic factors VEGF, HGF, and IGF-1 following co-culture of ASCs or ST2 cells with Gr1+, F4/80+, or CD11c+ cells.
Comparisons are made with monocultures (non). Data are presented as means ± standard deviation. *P < 0.0001, **P < 0.001, ***P < 0.005, versus
monocultured cells; Dunnett’s test (n = 5). ASC, adipose tissue-derived stromal cell; HGF, hepatocyte growth factor; IGF, insulin-like growth factor;
N.D., not detected; ST2 cell, bone marrow-derived stromal cell; VEGF, vascular endothelial growth factor.
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of IGF-1 was observed in co-culture of ASCs or ST2
cells with CD11c+ cells.
Secretion of matrix metalloproteinases following
interactions of ASCs or ST2 cells with inflammatory cells
MMP-2, -3, -9, and -13 secretions were determined in
media from co-cultures of ASCs or ST2 cells with Gr-1+,
F4/80+, or CD11c+ cells (Figure 5). Compared with
monocultured ASCs and ST2 cells, the secretions of
MMP-9, and -13 were markedly increased in the pres-
ence of F4/80+ and CD11c+ cells. However, monocul-
tured Gr-1+ cells secreted large quantities of MMP-9
and MMP-13, and the presence of these proteins was
decreased in media from co-cultures with ASCs or ST2
cells. In contrast, MMP-2 and -3 were detected at high
levels in supernatants from both mono- and co-culturedFigure 5 Secretions of MMP-2, -3, -9, and -13, following co-culture of ASCs
with monocultures (non). Data are presented as means ± standard deviatio
Dunnett’s test (n = 5). ASC, adipose tissue-derived stromal cell; MMP, matro
stromal cell.ASCs but were undetectable in all ST2-containing cell
cultures.
Secretion of anti-inflammatory factors, anti-angiogenesis
factors, and matrix metalloproteinase inhibitors following
interactions of ASCs or ST2 cells with inflammatory cells
Monocultured ASCs secreted inflammatory factors, angio-
genesis factors, and MMPs at high levels, whereas ST2
cells secreted these proteins only in the presence of in-
flammatory cells. In contrast, anti-inflammatory G-CSF
secretions from both cell types were dramatically in-
creased in co-cultures with inflammatory cells (Figure 6A).
Moreover, MIG secretions from both ASCs and ST2
cells increased by 2- to 2.5-fold in co-culture with
CD11c+ cells (Figure 6A). Among inflammatory cells,
only CD11c+ cells secreted the anti-angiogenic factor
angiostatin. Both mono- and co-cultured ASCs secretedor ST2 cells with Gr1+, F4/80+, or CD11c+ cells. Comparisons are made
n. *P < 0.0001, **P < 0.0005, ***P < 0.01, versus monocultured cells;
x mettaloproteinase; N.D., not detected; ST2 cell, bone marrow-derived
Figure 6 Secretions of the anti-inflammatory and the anti-angiogenic factors G-CSF, MIG, and angiostatin, and TIMP-1 and TIMP-2, following
co-culture of ASCs or ST2 cells with Gr1+, F4/80+, or CD11c+ cells. (A) Secretions of G-CSF and MIG. (B) Secretion of angiostatin. (C) Secretions of
TIMP-1 and TIMP-2. Comparisons are made with monocultures (non). Data are presented as means ± standard deviation. *P < 0.0001, **P < 0.0005,
***P < 0.05, versus monocultured cells; Dunnett’s test (n = 5). ASC, adipose tissue-derived stromal cell; G-CSF, granulocyte-colony stimulating factor;
MIG, monokine induced by interferon γ; N.D., not detected; ST2 cell, bone marrow-derived stromal cell; TIMP, tissue inhibitors of metalloproteinase.
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in the presence of CD11c+ cells (Figure 6B). Co-culture
with inflammatory cells did not affect the secretion of
TIMP-1 from ASCs or the secretion of TIMP-2 from
both ASCs and ST2 cells (Figure 6C).
Discussion
Induction of inflammatory factors as well as accumula-
tion of various types of inflammatory cells is critical to
self-regeneration during wound healing of animal organs
[6]. Accordingly, inflammatory cells and secretory fac-
tors initiate tissue regeneration by replenishing cells and
extracellular components. In the present in vivo imaging
experiments, bone marrow-derived inflammatory cells
were involved in the first stage of the wound healing
process in the punched hole of the mouse ears. More-
over, in subsequent ASC and ST2 cell culture experi-
ments, the expression of cell markers differed between
cell types (Table 1) and as ASCs secreted high levels of
angiogenic growth factors, cytokines, and chemokines
in vitro, we expected more extensive angiogenic effects
with ASCs than with ST2 cells in vivo. However,
in vivo observations of angiogenesis and inflammation
showed no significant differences between the effects
of transplanted ASCs and ST2 cells, although ASCs
produced greater quantities of angiogenic growth fac-
tors such as VEGF, HGF, and IGF-1 than ST2 cells. In
contrast, co-culture of ST2 cells with inflammatory
Gr1+ cells (neutrophils, granulocytes) or F4/80+ cells
(macrophages) markedly increased the production of
angiogenic growth factors. These data suggest that ST2cells acquire angiogenic potential following interac-
tions with inflammatory cells, which may migrate to-
ward chemotactic inflammatory factors such as MIP,
KC, MCP-1, and IL-6 [11,12]. Moreover, following ex-
posure to inflammatory cells, these proteins were se-
creted at high levels from both cell types, indicating
that ASCs and ST2 cells exert similar effects under
these conditions. In further experiments, extensive se-
cretion of chemokines and growth factors from ASCs
was associated with hemangioma formation, with
hyper-inflammation and extensive angiogenesis. How-
ever, in co-culture with inflammatory cells, ASCs se-
creted high levels of growth factors, anti-inflammatory
factors, and angiogenic inhibitors such as G-CSF [13],
MIG [14], angiostatin [15], and IL-6, which act as both
pro-inflammatory and anti-inflammatory factors [16,17].
In contrast, secretions of pro-inflammatory and angio-
genic factors were less abundant from ST2 cells than from
ASCs and did not include anti-inflammatory factors or in-
hibitors of angiogenesis. Thus, inflammatory and angio-
genic processes are transient in healthy organisms, and a
dynamic balance of pro- and anti-inflammatory, and pro-
and anti-angiogenic factors, MMPs, and TIMPs, act as ac-
celerators and brakes, respectively. Accordingly, trans-
planted ASCs and ST2 cells were eradicated in healthy
mice (Figure 2D,E), reflecting phagocytosis by macro-
phages and a healthy balance of inflammatory processes.
Macrophages are classified as pro-inflammatory (clas-
sically activated M1 macrophage phenotype) or anti-
inflammatory (alternatively activated M2 macrophage
phenotype) [18]. In the present studies using CD11c as a
Hattori and Ishihara Stem Cell Research & Therapy  (2015) 6:70 Page 8 of 10marker of pro-inflammatory macrophages [19], few
CD11c+ cells had migrated into the ASC and ST2 cell
transplantation area at 3 days after the transplantation,
although migrant F4/80+ cells were abundant at 7 days.
Moreover, the migration of pro-inflammatory macro-
phages was greater after transplantation of ASCs and
ST2 cells than after perforation of ear tissues. However,
disruption of transplanted ASCs and ST2 cells was ob-
served after 7 days and not all transplanted cells become
engrafted, indicating that stromal cell transplants act as ini-
tial inducers of inflammation in the first stage of the wound
healing process. Subsequently, these cells are attacked by
neutrophils, granulocytes, and pro-inflammatory macro-
phages and are then phagocytosed by macrophages that
mediate paracrine effects and facilitate the recovery of dam-
aged tissue in a transplant-dependent fashion.
Cell-based therapies using ASCs are highly efficacious
for decubitus ulcers [20,21], reportedly reflecting the ac-
tions of angiogenenic factors, such as HGF and VEGF
[22]. Among MMPs that are involved in cutaneous
wound healing [23], MMP-9 plays a role in keratinocyte
migration and epithelialization, whereas MMP-13 plays
a role in epithelialization, angiogenesis, and contraction
of wound healing processes [24]. In the present study,
the presence of ASCs or ST2 cells inhibited excessive se-
cretion of MMP-9 and MMP-13 from neutrophils but
caused excessive secretion of MMP-9 and MMP-13 in
the presence of macrophages (Figure 5). Thus, in
addition to angiogenic factors, MMP-9 and MMP-13
may play a role in wound healing in patients with dia-
betes. However, previous studies suggest that high ex-
pression of MMP-9 results in inadequate wound healing
of foot ulcers in patients with diabetes [25] and con-
tribute to exercise inflammation. High expression of
MMP-9 is reportedly associated with protein tyrosine
phosphatase-1B in skin, and aberrant serum growth
factor levels prevent healing of diabetic foot ulcers [26].
In another report, because the ratio of MMP-9 and
TIMP-1 is positively correlated with poor healing foot
ulcers in patients with diabetes [27], we surmise that
the issue is not high expression of MMP-9 but an inad-
equate ratio of MMP-9 and TIMP-1.
Both of the present cell types have been investigated as
cell-based therapies for autoimmune diseases such as
rheumatoid arthritis and osteoarthritis [28-30]. Moreover,
ASCs and BMCs have potential hematopoietic roles in
osteogenesis, chondrogenesis, adipogenesis, myogenesis,
and angiogenesis [31-33], and previous comparisons of
ASCs and BMCs show similar potential properties in vivo
and in vitro [25,34-38]. ASC transplantations have also
been effective in in vivo experiments, which showed that
ASCs induce immune tolerance and prevent arthritis by
secreting both pro-inflammatory and anti-inflammatory
factors [39,40]. Moreover, articular rheumatism inducesintense synovial inflammation and pannus formation due
to excessive synoviocyte growth, leading to erosion of
bones and disruption of cartilage tissues. Joint tissue com-
prises various cell types, such as fibroblasts, endothelial
cells, and inflammatory cells, which further comprise neu-
trophils, macrophages, and T cells, which secrete various
proteases and cytokines. Accordingly, MMPs secreted
from chondrocytes and activated synoviocytes are in-
volved in cartilage destruction [41], and MMP-3 and IL-6
are known markers of rheumatoid arthritis and osteoarth-
ritis. The present data show markedly elevated secretion
of MMPs in co-cultures of ASCs with inflammatory cells,
particularly with macrophages (Figure 5), although TIMP-
2 secretions were not affected by co-culture with inflam-
matory cells (Figure 6C). In contrast, ST2 cells did not
secrete MMP-2 or MMP-3, and their interactions with in-
flammatory cells were weaker than those of ASCs, sug-
gesting that secretions of various MMPs and chemokines
and stimulation of inflammatory cells may complicate the
use of ASCs for the treatment of rheumatoid arthritis or
osteoarthritis. In particular, ASCs may replace bone mar-
row with adipose tissues and cause bone loss in the elderly
[42]. Accordingly, a close relationship has been shown be-
tween osteoblasts and adipocytes [43], which moderate
each other inversely [44]. Hence, prolonged inflammation
may ultimately cause or exacerbate chronic inflammatory
disease.
Conclusions
Transplantation of ASCs and ST2 cells induced the mi-
gration of bone marrow-derived inflammatory cells such
as neutrophils and macrophages. Thus, the effects of
cell-based therapy using ASCs and ST2 cells are
depended on paracrine effects that are mediated by che-
mokines, cytokines, growth factors, and MMPs, which
are expressed in response to interactions between trans-
planted cells and bone marrow-derived inflammatory
cells. Accordingly, the present data show that the para-
crine effects of transplanted cells are influenced by in-
flammatory cells and maintained by a balance of secreted
inhibitors. Thus, the use of ASCs for cell-based therapy
requires close attention in patients with a history of
chronic inflammatory disease.
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Additional file 1: Real-time image of the 7th day after making a
hole to the ear of the mouse into which GFP+ BMCs were injected.
GFP+ BMCs circulating in vessels migrated into the surrounding tissue of
a 2-mm diameter hole.
Additional file 2: Real-time image of transplanting PKH26-labeled
ASCs into the ear of the mouse in which GFP+ BMCs were injected.
The first image is GFP+ BMCs circulating in vessels immediately after
injection, and the second is immediately after PKH26-labeled ASCs were
transplanted. The next one is GFP+ BMCs migrating into the
Hattori and Ishihara Stem Cell Research & Therapy  (2015) 6:70 Page 9 of 10transplantation site of PKH26-labeled ASCs on the 7th day after the
transplantation, and the last one is the magnified image.
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